Alembic Pharmaceuticals has appointed M/s. KKC & Associates LLP as its new Statutory Auditors for a five-year term starting from the upcoming AGM, replacing M/s. K.C. Mehta & Co. LLP, subject to shareholder approval. The decision was made during the Board Meeting on May 6, 2025, where they also approved a dividend of Rs. 11 per equity share.